PAK4 and breast carcinoma: Importantly, while overexpression of PAK4 caused decreased sensitivity to tamoxifen in MCF7 human breast cancer cells, a specific inhibitor of group II PAKs, GNE-2861, restored the sensitivity to tamoxifen in the tamoxifen-resistant MCF-7/LCC2 cells.